Evidence map›Paper›PMID 37766821›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2023

Study of the effect of active pharmaceutical ingredients of various classes of BCS on the parameters of thermosensitive systems based on poloxamers.

E O Bakhrushina, A I Khodenok, V S Pyzhov, P G Solomatina, N B Demina, T V Korochkina, I I Krasnyuk

Open access · hybridAbstract read
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

E O BakhrushinaI.M. Sechenov First Moscow State Medical University (Sechenov University), A.P.Nelyubin Institute of Pharmacy, Department of Pharmaceutical Technology, 96 Vernadsky Avenue, building 1 119571, Moscow, Russia.
A I KhodenokI.M. Sechenov First Moscow State Medical University (Sechenov University), A.P.Nelyubin Institute of Pharmacy, Department of Pharmaceutical Technology, 96 Vernadsky Avenue, building 1 119571, Moscow, Russia.
V S PyzhovI.M. Sechenov First Moscow State Medical University (Sechenov University), A.P.Nelyubin Institute of Pharmacy, Department of Pharmaceutical Technology, 96 Vernadsky Avenue, building 1 119571, Moscow, Russia.
P G SolomatinaI.M. Sechenov First Moscow State Medical University (Sechenov University), A.P.Nelyubin Institute of Pharmacy, Department of Pharmaceutical Technology, 96 Vernadsky Avenue, building 1 119571, Moscow, Russia.
N B DeminaI.M. Sechenov First Moscow State Medical University (Sechenov University), A.P.Nelyubin Institute of Pharmacy, Department of Pharmaceutical Technology, 96 Vernadsky Avenue, building 1 119571, Moscow, Russia.
T V KorochkinaI.M. Sechenov First Moscow State Medical University (Sechenov University), A.P.Nelyubin Institute of Pharmacy, Department of Pharmaceutical Technology, 96 Vernadsky Avenue, building 1 119571, Moscow, Russia.
I I KrasnyukI.M. Sechenov First Moscow State Medical University (Sechenov University), A.P.Nelyubin Institute of Pharmacy, Department of Pharmaceutical Technology, 96 Vernadsky Avenue, building 1 119571, Moscow, Russia.
Sechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The development of thermosensitive Materials and methods: The biopharmaceutical classification system (BCS) was chosen as the basis. Accordingly, the following APIs were selected for the experiment: BCS class I - lidocaine hydrochloride and ketorolac tromethamine, class II - ibuprofen and diclofenac, class III - pyridoxine hydrochloride and ribavirin, class IV - furosemide and abiraterone. To create thermoreversible compositions, previously studied for stability combinations of poloxamer 407, poloxamer 188 and PEG 1500 were used.At the stage of preparation of experimental samples formulations with APIs of classes II and IV of BCS were excluded, since the solubilizing ability of poloxamers is not enough to obtain stable combined complexes. Results: In the course of the work, the following results were obtained: BCS class I APIs significantly reduced the phase transition temperature of the matrix of poloxamers 407 and 188, while the addition of PEG 1500 eliminated the effect of APIs on gels; BCS class III APIs practically did not affect the rheological properties of the studied combinations; the phase transition temperature of the gel based on poloxamer 407 did not change with the addition of Class I and Class III APIs.Nevertheless, the obtained results made it possible to reveal the regular behavior of

Indexed as

BCSIn situ systemsPhase transition temperaturePoloxamersRheologyThermosensitive systems

Identifiers

PMID37766821
PMCPMC10520434
OpenAlexW4386566247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.